Clinical trial
Bevacizumab and Lomustine for Recurrent GBM
NCT01290939 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT01290939 |
|---|---|
| Title | Bevacizumab and Lomustine for Recurrent GBM |
| Official title | Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme, Cognition Disorders, Disability Evaluation |
| Intervention type | Biological, Drug, Genetic, Other, Procedure |
| Interventions | bevacizumab, lomustine, DNA methylation analysis, laboratory biomarker analysis, cognitive assessment, quality-of-life assessment |
| Enrollment | 592 |
| Start date | Oct 1, 2011 |
| Primary completion | Oct 1, 2015 |
| Completion | Apr 1, 2020 |
| First posted | Feb 7, 2011 |
| Last update posted | Feb 15, 2021 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: